These results indicated that the combination of PARP and BLM inhibition by small molecule inhibitors (olaparib and ML216, respectively) exerted synthetic lethality effects, which provided a therapeutic strategy to kill olaparib-resistant tumor cells. This evidence concerns the gene PARP1 and neoplasm.